The proposed acquisition of US-based Snapdragon Chemistry by the Chinese CDMO Asymchem Laboratories has been abandoned. The two firms were unable to agree mitigation terms that would satisfy the US Treasury’s Committee on Foreign Investment in the United States (CFIUS).
SK Capital Partners have made an investment in VanDeMark Chemical in partnership with Comvest Partners, which has been a co-owner since 2019. The amount involved was not disclosed but VanDeMark said that this would “serve as a catalyst for a new strategic direction as the company seeks to deepen and expand its presence in fine chemistries for the global life science market”.
Evotec has bought the German manufacturing operations of Japan’s Central Glass for a nominal €1. The deal is subject to customary closing conditions and is expected to close on 1 November. The business will be renamed Evotec Drug Substance (Germany).
SK Pharmteco affiliate Ampac Fine Chemicals (AFC) has added a complex molecule chemistry and engineering centre at its main site in Rancho Cordova, California. “This expands upon our core technologies such as energetic chemistry, high potency, chromatography and continuous processing”, said Dr John Jacobsen, executive director of R&D.
A new CPHI report highlights a significant shift in the pharma outsourcing market
Siegfried has held a groundbreaking ceremony for the largest construction project in its history. The Swiss CDMO will be investing up to CHF 100 million on a large-scale production facility at Minden, Germany. This will have up to 100 m3 of additional reactor capacity for API production when it is commissioned in 2024.
Edgewater Capital Partners, a lower middle-market private equity firm which has made previous investments in life Sciences and pharma services, has acquired GL Chemtec of Oakville, Ontario, a CRO which offers chemistry R&D and scale-up services to support API development, plus advanced materials for drug delivery, medical devices and other life science applications. No financial details were disclosed.
